Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
stocks
WiseTech result disappoints, but the future looks bright
Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,243.00 | 9.00 | 0.10% |
CAC 40 | 7,703.90 | 58.70 | -0.76% |
DAX 40 | 23,902.21 | 137.71 | -0.57% |
Dow JONES (US) | 45,524.66 | 112.24 | -0.25% |
FTSE 100 | 9,187.34 | 29.48 | -0.32% |
HKSE | 25,077.62 | 78.80 | 0.32% |
NASDAQ | 21,450.48 | 254.68 | -1.17% |
Nikkei 225 | 42,718.47 | 110.32 | -0.26% |
NZX 50 Index | 12,930.73 | 27.65 | 0.21% |
S&P 500 | 6,457.63 | 44.23 | -0.68% |
S&P/ASX 200 | 8,973.10 | 4.10 | 0.05% |
SSE Composite Index | 3,857.93 | 14.33 | 0.37% |